The short version
Estradiol, the main estrogen your ovaries made before menopause, comes in several FDA-approved forms. For hot flashes and night sweats, oral and transdermal (through-the-skin) forms work about equally well: The Menopause Society’s 2022 position statement cites a meta-analysis that found no significant difference between them for relieving these symptoms.
Where the forms differ is how the estrogen reaches your blood. A pill is absorbed from the gut and passes through the liver first. A patch, gel or spray goes through the skin and skips that first pass. That route difference is the main reason clot and stroke risks look different in the studies below.
This article is general information, not medical advice or a dosing recommendation. Decisions about starting, changing or stopping a prescription belong with a licensed clinician who knows your history.
The forms side by side
| Form | How it is used | FDA-approved examples | Practical notes |
|---|---|---|---|
| Pill | Daily tablet | Generic estradiol (Estrace) | Simplest; passes through the liver first |
| Patch | Stuck on the skin, changed once or twice a week depending on the product | Climara, Vivelle-Dot, Minivelle | Steady delivery; can irritate skin or lift off |
| Gel | Rubbed on the arm or thigh daily | Divigel, EstroGel, Elestrin | Must dry first; can transfer to others by skin contact |
| Spray | Sprayed on the forearm daily | Evamist | Label warns about secondary exposure in children and pets |
| Systemic ring | Vaginal ring replaced every 3 months | Femring | Higher-dose ring for whole-body symptoms; not the same as low-dose Estring |
| Combined | Estrogen plus a progestogen in one product | Climara Pro and CombiPatch (patches), Bijuva (capsule) | Covers uterine protection in a single product |
Low-dose vaginal creams, tablets and the Estring ring are a different category: they treat vaginal and urinary symptoms with minimal absorption, and we cover them in our vaginal estrogen guide.
Blood clots and stroke: where the route matters
Clots (venous thromboembolism). In two UK nested case-control studies covering 80,396 women with a clot and 391,494 controls, oral hormone therapy was linked to a higher clot risk than no therapy (adjusted odds ratio 1.58), while transdermal therapy was not (0.93, confidence interval 0.87 to 1.01). Among oral products, estradiol carried less risk than conjugated equine estrogens (Vinogradova et al., BMJ 2019, PMID: 30626577).
The French ESTHER study found the same pattern: odds ratio 4.2 for current oral estrogen users and 0.9 for transdermal users, compared with non-users. It also linked norpregnane progestins, but not micronized progesterone, to higher clot risk (Canonico et al., Circulation 2007, PMID: 17309934).
Stroke. In a UK database study of 15,710 strokes, low-dose patches were not associated with more strokes (rate ratio 0.81), higher-dose patches were (1.89), and oral therapy at any dose was (1.28) (Renoux et al., BMJ 2010, PMID: 20525678).
The caveat. These are observational studies, so other differences between women who chose pills or patches could explain part of the gap. The Menopause Society says comparative randomized trial data are lacking and that it is unknown whether non-oral routes lower these risks in trials, while noting that observational studies have not shown higher clot risk with transdermal estrogen (NAMS 2022, PMID: 35797481).
What else differs in daily life
• Gallbladder: estrogen raises the risk of gallstones; observational studies report lower risk with transdermal than oral therapy, not yet confirmed in trials (NAMS 2022).
• Transfer to others: gels and sprays can rub off onto children, partners and pets. The Divigel label tells users to keep children from touching the application site and to wash it if contact happens, and it notes pets can be exposed too.
• Skin: application-site reactions such as redness and itching are possible with patches and gels, and the Divigel label says not to cover the area with clothing until the gel has dried.
• Cost: prices vary by form and pharmacy; current prices are on our menopause treatment cost page.
If you have a uterus, add a progestogen
Estrogen on its own thickens the uterine lining. In the 3-year PEPI trial, 27.7% of women on estrogen alone developed simple hyperplasia versus 0.8% on placebo, while the estrogen-plus-progestogen regimens had rates similar to placebo (PEPI Writing Group, JAMA 1996, PMID: 8569016).
This applies to every systemic form above, patch and gel included. Our progesterone guide explains the choices. People without a uterus generally take estrogen alone.
What changed on the labels in 2026
In November 2025 the FDA started removing the broad boxed warnings that had been on menopause hormone products since 2003. On February 12, 2026 it approved the first six updated labels (Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva), removing the boxed-warning statements on cardiovascular disease, breast cancer and probable dementia (FDA).
Two things did not change. Systemic estrogen-alone products keep a boxed warning about endometrial cancer in women with a uterus, and the cardiovascular and breast cancer warnings stay in the body of the label (FDA labeling request). The FDA is approving updates in batches, so some products still showed the older boxed warning when we checked on October 8, 2026; Evamist’s posted label was one (DailyMed).
The FDA also asked that systemic labels add that starting hormone therapy can be considered for moderate to severe hot flashes in women under 60 or within 10 years of menopause. That matches The Menopause Society’s view that, without contraindications, the benefit-risk balance is favorable in that window (NAMS 2022, PMID: 35797481).
Compounded “bioidentical” estrogen
FDA-approved estradiol is already bioidentical: it is the same molecule the ovaries make. Compounded hormone creams and pellets are mixed by a pharmacy and are not FDA-approved. The Menopause Society says there is insufficient evidence to support their routine use, flags risks of over- and under-dosing, and says saliva or urine hormone tests used to adjust them are unreliable (NAMS 2022, PMID: 35797481). It reserves compounding for cases such as an allergy to an ingredient in approved products.
When you compare online menopause providers, ask whether they prescribe FDA-approved products and which pharmacy fills them.
Safety: who should not use systemic estrogen
The current Divigel label lists these contraindications, which are typical for systemic estrogen (DailyMed):
• Abnormal genital bleeding that has not been diagnosed
• Current or past breast cancer, or another estrogen-dependent cancer
• A current or past blood clot in the legs or lungs, or a past stroke or heart attack
• Liver disease, or an inherited clotting disorder such as protein C, protein S or antithrombin deficiency
Report new vaginal bleeding after menopause, leg swelling or pain, chest pain, sudden shortness of breath, or sudden changes in vision or speech to a clinician promptly. Hormone therapy should be reviewed periodically with your prescriber.
Comparing providers and costs
If you are weighing online care, our women’s HRT comparison scores approved partners on price, what is included and trust signals; online menopause HRT compared and how to get HRT online cover the process. Provider-specific details are in our Winona review.
Disclosure
CalcMyPeptide may earn commissions from some telehealth providers on our comparison and review pages, which list only vetted providers whose affiliate programs have approved us or are reviewing our application. This article contains no paid links. How we rank providers and get paid: telehealth disclosure and methodology.